Denosumab biosimilar - GlycoNex
Alternative Names: SPD Denosumab biosimilar - GlycoNex; SPD-8; SPD8-P; SPD8-RLatest Information Update: 16 Jun 2026
At a glance
- Originator GlycoNex; Mitsubishi Gas Chemical - Nisshin Pharma (JV)
- Developer GlycoNex
- Class Antihypercalcaemics; Antineoplastics; Antirheumatics; Calcium regulators; Immunotherapies; Monoclonal antibodies; Osteoporosis therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; RANK ligand inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Osteoporosis
- Preclinical Cancer